Functions of CJC 1295 w DAC
Growth hormone releasing hormone (GHRH) has been modified a number of times to produce analogues that preserve some of the hormone’s effects while eliminating others. One of those modifications, CJC-1295, consists of just the first 29 amino acids of GHRH. This analogue of GHRH, which is technically a maleimido derivative of hGRF(1-29), was created in an effort to produce a more soluble GH secretagogue that is easier to produce in large quantities but still preserves the physiologic actions of GHRH.
CJC-1295 Versus CJC-1295 DAC
CJC-1295 is a modified version of the first 29 amino acids of GHRH, which means it is chemically similar to other GHRH analogues, like Sermorelin. It is most similar to modified GRF (1-29), but the two peptides are not identical. A great deal of confusion arises because of the similarities between these peptides and because CJC-1295 was originally created with an added chemical compound called the drug affinity complex (DAC).
DAC is added to the molecule, with the help of a lysine linker, to protect the peptide while it circulates in the blood stream. By allowing peptides to bind to the common blood protein albumin, DAC helps to ensure that the half-life of CJC-1295 is much longer than similar molecules like GRF (1-29).
Half-life of CJC-1295-DAC compared to standard growth hormone releasing factor (GRF)
Source: Oxford Academic
Originally, ConjuChem Biotechnologies, the developer of DAC, referred to the molecule containing DAC as simply CJC-1295. Confusion arose, however, because the peptide was also being offered without DAC. To avoid confusion, CJC-1295 that contains DAC is called CJC-1295-DAC and when it does not contain DAC it is referred to as CJC-1295 or CJC-1295-no DAC.
